Cellectis
Manufacturing · France · 201-500 Employees
View Company Info for Free
Overview
Headquarters
8 Rue De La Croix Jarry, Paris, Ile-de-F...Phone Number
+33 181691600Website
www.cellectis.comRevenue
$75.3 MillionStock Symbol
ALCLSIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Cellectis
Cellectis is a biopharmaceutical company founded in 1999 and headquartered in Paris, France. The company specializes in developing innovative pharmaceutical products and therapies. As a publicly traded organization since 2019, Cellectis focuses on manufacturing pharmaceuticals with operations across Europe and North America. The company maintains a strong presence in both B2B and B2C markets, leveraging mobile applications as part of their technology infrastructure.Explore more
Cellectis Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cellectis your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Cellectis is spiking on competitors!
Check if Cellectis has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Cellectis recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Cellectis
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Cellectis launches new products
Cellectis, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Cellectis had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Cellectis has new funding data
Recommended Actions
Find VP level buyers at Cellectis
Find 3 more new buyers
Company Profile Activity
Activity Insights
Cellectis is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Cellectis is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Cellectis.
Cellectis financials insights
Gather financial insights about Cellectis, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Corporate Investment
$22.2M
2015
Stock Offering
$129M
2018
Stock Offering
$163.7M
Other Financing Round
$164M
2022
Debt
$42.6M
Cellectis Tech Stack
A closer look at the technologies used by Cellectis
See more technologies
Most Recent Scoops
Person-Based
Bioengineering, Medical Research
Left Company
Executive Move
Executive Moves, Left Company
Person-Based
Award
Person-Based
Pharmaceuticals
Cellectis News & Media
CLLS INVESTOR ALERT: Investigation of Cellectis S.A. Announced by Holzer & Holzer, LLC
ATLANTA, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Cellectis S.A. (“Cellectis” or the “Company”) (NASDAQ: CLLS) complied with federal securities laws. On September 14, 2026, Cellectis announced that it will “exit the development of lasme-cel and eti-cel[.]” On this news, the price of the Company’s stock dropped.Cellectis (CLLS) Exits Two CAR-T Programs. Can Gene Editing Justify the Clinical Reset?
Cellectis S.A. (NASDAQ:CLLS) announced on September 14 that its board approved a strategic transformation on September 11. It will exit internal development of lasme-cel and eti-cel, seek partners for those cancer therapies, and prioritize two preclinical programs for severe lipid disorders. The shift moves the internal pipeline toward in vivo treatment, delivering editing machinery directly […]Cellectis Announces Strategic Transformation To In Vivo Gene Editing Company
NEW YORK, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a pioneer in gene editing, announced that on September 11, 2026, the board of directors approved a strategic transformation to become an in vivo gene editing company focused on developing long-lasting treatments for chronic diseases.Cellectis to Host Conference Call and Webcast on September 14 to Provide a Business Update
NEW YORK, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced that it will host a conference call and webcast on Monday, September 14, 2026 to provide a business update.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Cellectis
Sign Up For FreeTo access detailed company insights
Cellectis is a biopharmaceutical company founded in 1999 and headquartered in Paris, France. The company specializes in developing innovative pharmaceutical products and therapies. As a publicly traded organization since 2019, Cellectis focuses on manufacturing pharmaceuticals with operations across Europe and North America. The company maintains a... Read More
